Global Connective Tissue Disease Market Research Report- forecast till 2023

Report Information

More information from: https://www.marketresearchfuture.com/reports/4977

Global Connective Tissue Disease Market Research Report- forecast till 2023

Report / Search Code: MRFR/Pharma/3542-HCRR

Publish Date: May, 2019

Request Sample

| Price            | 1-user PDF : $ 4450.0 | Enterprise PDF : $ 6250.0 |

Description:

Connective Tissue Disease Market Research Report information: Diagnosis (X-ray Examination, Antinuclear Antibody Test, Treatment (Non-Steroidal Anti-Inflammatory, Cortisone/Steroids, Antimalarial, Cytotoxic Drugs), End User - Global forecast till 2023

Market Scenario

Connective tissues are a group of cellular congregations that provide support and structure to the human body. Connective tissue disease is a group of disorders which involves these protein rich tissues. Protein rich tissues play an important role of supporting organs and other parts of the body. Connective tissue disorders involves multiple organs and organ systems such as, skin, joints, muscles, lungs, kidneys, eyes, heart, gastrointestinal tract, and blood vessels. More than 200 disorders affect the connective tissues. According to a study published in Pan African Medical Journal in 2017, it is found that mixed connective tissue disorders are more frequent among Asians, and in the African population. It is also reported that among Asian population, the condition is more prevalent in China, and Japan. In the European region, the disorder is more prevalent in Italy, Hungary, Norway, and Poland.

The specific cause of this disorder is unknown but the genetic patterns are considered to escalate the risk for developing connective tissue diseases. The connective tissue diseases arises due to changes in certain genes are often known as heritable disorders of connective tissue. Some of the common inherited disorders are Ehlers-Danlos syndrome (EDS), Epidermolysis bullosa (EB), Marfan Syndrome, and Osteogenesis imperfect. EDS is an amalgamation of more than 10 disorders, characterized by stretchy skin, over-flexible joints, and abnormal growth of scar tissue. Various autoimmune diseases are also associated with connective tissue disorders, which includes polymyositis and dermatomyositis, rheumatoid arthritis (RA), Sjögren's syndrome, and vasculitis. Mixed connective tissue disease (MCTD) is another rare autoimmune disease, consisting of characteristic features of several diseases such as lupus, polymyositis or dermatomyositis, scleroderma, and rheumatoid arthritis. According to the National Center for Advancing Translational Medicines, currently there is no cure available for this condition but certain medications such as corticosteroids, immunosuppresive drugs, and nonsteroidal anti-inflammatory drugs (NSAIDs) help in the management of symptoms. It is also stated that MCTD is more frequent in females with a male to female ratio of 1:3, and the typical age of onset of MCTD is between 15-25 years.

Notably, the market is expected to expand in the near future due to the rising prevalence of various connective tissue disorders, high unmet needs of current treatment, and surge in the research and development expenditure.

Despite these drivers, there are some issues associated with connective tissue disease market. Lack of infrastructure in the middle and low income countries may hamper the growth of the market.

It is estimated that connective tissue disease market is expected to grow at a CAGR 11.5% during the forecast period of 2017-2023.

Intended Audience

- Hospitals
- Diagnostic clinics
- Research and Development (R&D) Companies
- Government Research Institute
- Academic Institutes and Universities
Segmentation

The connective tissue disease market is segmented on the basis of diagnosis, treatment, and end-user.

On the basis of diagnosis, market is segmented into physical examination, X-ray examination, ANA (Antinuclear Antibody Test), and others.

On the basis of treatment, market is classified into non-steroidal anti-inflammatory drugs (NSAIDs), cortisone drugs/steroids, antimalarial drugs, cytotoxic drugs, and others.

On the basis of end-user, market is segmented into hospital, diagnostic clinics, and others.

Regional Analysis

The Americas dominate the connective tissue disease market owing to the rising awareness among people, and increasing healthcare expenditure. As per the facts suggested by the Centers for Disease Control and Prevention (CDC), out of the total annual healthcare expenditure, 86% is for people with chronic health conditions in the United States.

Europe holds the second position in the connective tissue disease market. It is expected that the support provided by government bodies for research & development and improvement in reimbursement policies in healthcare will drive the market in Europe.

Asia Pacific is the fastest growing market connective tissue disease, owing to a huge patient pool, developing healthcare technology, and rising healthcare expenditure in some countries within this region. According to the Australian Institute of Health and Welfare, in the years 2015 to 2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than expenditure of 2014–15.

The Middle East & Africa has the lowest market for connective tissue disease due to lack of technical knowledge and poor medical facilities.

Key Players

Some of key the players in the market are Abbott Laboratories, Bayer AG, F. Hoffmann-La Roche Ltd, Pfizer, AutoImmune Inc., Johnson & Johnson, Amgen Inc., AstraZeneca, Eli Lilly and Company, Biogen, LUPIN, and others.

Research Methodology
Contents

Table of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter's Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants
Chapter 6. Global Connective Tissue Disease Market, by Diagnosis

6.1 Introduction
6.2 Physical Examination
6.2.1 Market Estimates & Forecast, 2016 – 2023
6.3 X-ray Examination
6.3.1 Market Estimates & Forecast, 2016 – 2023
6.4 ANA (Antinuclear Antibody Test)
6.4.1 Market Estimates & Forecast, 2016 – 2023
6.5 Others
6.5.1 Market Estimates & Forecast, 2016 – 2023

Chapter 7. Global Connective Tissue Disease Market, by treatment

7.1 Introduction
7.2 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
7.2.1 Market Estimates & Forecast, 2017 – 2023
7.3 Cortisone Drugs/Steroids
7.3.1 Market Estimates & Forecast, 2017 – 2023
7.4 Antimalarial Drugs
7.4.1 Market Estimates & Forecast, 2017 – 2023
7.5 Cytotoxic Drugs
7.5.1 Market Estimates & Forecast, 2017 – 2023
7.6 Others
7.6.1 Market Estimates & Forecast, 2017 – 2023

Chapter 8. Global Connective Tissue Disease Market, by End User

8.1 Introduction
8.2 Hospitals
8.2.1 Market Estimates & Forecast, 2017 – 2023
8.3 Clinics
8.3.2 Market Estimates & Forecast, 2017 – 2023
8.4 Others

Chapter 9. Global Connective Tissue Disease Market, by Region

9.1 Introduction
9.2 Americas
9.2.1 North America
9.2.1.1 U.S.
9.2.1.1 Canada
9.2.2 South America
9.3 Europe
9.3.1 Western Europe
9.3.1.1 Germany
9.3.1.2 France
9.3.1.3 Italy
9.3.1.4 Spain
9.3.1.5 U.K.
9.3.1.6 Rest of Western Europe
9.3.2 Eastern Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 Republic of Korea
9.4.6 Rest of Asia Pacific
9.5 The Middle East & Africa
9.5.1 United Arab Emirates
9.5.2 Saudi Arabia
9.5.3 Oman
9.5.4 Kuwait
9.5.5 Qatar
9.5.6 Rest of the Middle East & Africa

Chapter 10 Company Landscape
10.1 Introduction
10.2 Market Share Analysis
10.3 Key Development & Strategies
10.3.1 Key Developments

Chapter 11 Company Profiles
11.1 Abbott Laboratories
11.1.1 Company Overview
11.1.2 Types Overview
11.1.3 Financials
11.1.4 SWOT Analysis
11.2 Bayer AG
11.2.1 Company Overview
11.2.2 Types Overview
11.2.3 Financial Overview
11.2.4 Key Developments
11.2.5 SWOT Analysis
11.3 F. Hoffmann-La Roche Ltd
11.3.1 Company Overview
11.3.2 Types Overview
11.3.3 Financial Overview
11.3.4 Key Development
11.3.5 SWOT Analysis
11.4 Pfizer
11.4.1 Company Overview
11.4.2 Types/Business Segment Overview
11.4.3 Financial Overview
11.4.4 Key Development
11.4.5 SWOT Analysis
11.5 AutoImmune Inc.
11.5.1 Company Overview
11.5.2 Types Overview
11.5.3 Financial overview
11.5.4 Key Developments
11.6 Johnson & Johnson
11.6.1 Company Overview
11.6.2 Types Overview
11.6.3 Financial Overview
11.6.4 Key Developments
11.7 Amgen Inc.
11.7.1 Overview
11.7.2 Types Overview
11.7.3 Financials
11.7.4 Key Developments
11.7.5 SWOT Analysis
11.8 Others

Chapter 12 MRFR Conclusion
12.1 Key Findings
12.1.1 From CEO’s View Point
12.1.2 Unmet Needs of the Market
12.2 Key Companies to Watch
12.3 Prediction of Connective Tissue Disease industry

Chapter 13 Appendix
LIST OF TABLES
Table 1 Connective Tissue Disease Industry Synopsis, 2017 – 2023
Table 2 Connective Tissue Disease Market Estimates and Forecast, 2017 – 2023, (USD Million)
Table 3 Connective Tissue Disease Market by Region, 2017 – 2023, (USD Million)
Table 4 Connective Tissue Disease Market by Diagnosis, 2017 – 2023, (USD Million)
Table 5 Connective Tissue Disease Market by Treatment, 2017 – 2023, (USD Million)
Table 6 Connective Tissue Disease Market by End Users, 2017 – 2023, (USD Million)
Table 7 North America Connective Tissue Disease Market by Diagnosis, 2017 – 2023, (USD Million)
Table 8 North America Connective Tissue Disease Market by Treatment, 2017 – 2023, (USD Million)
Table 9 North America Connective Tissue Disease Market by End Users, 2017 – 2023, (USD Million)
Table 10 US Connective Tissue Disease Market by Diagnosis, 2017 – 2023, (USD Million)
Table 11 US Connective Tissue Disease Market by Treatment, 2017 – 2023, (USD Million)
Table 12 US Connective Tissue Disease Market by End Users, 2017 – 2023, (USD Million)
Table 13 Canada Connective Tissue Disease market by Diagnosis, 2017 – 2023, (USD Million)
Table 14 Canada Connective Tissue Disease Market by Treatment, 2017 – 2023, (USD Million)
Table 15 Canada Connective Tissue Disease market by End Users, 2017 – 2023, (USD Million)
Table 16 South America Connective Tissue Disease Market by Diagnosis, 2017 – 2023, (USD Million)
Table 17 South America Connective Tissue Disease Market by Treatment, 2017 – 2023, (USD Million)
Table 18 South America Connective Tissue Disease Market by End Users, 2017 – 2023, (USD Million)
Table 19 Europe Connective Tissue Disease Market by Diagnosis, 2017 – 2023, (USD Million)
Table 20 Europe Connective Tissue Disease Market by Treatment, 2017 – 2023, (USD Million)
Table 21 Europe Connective Tissue Disease Market by End Users, 2017 – 2023, (USD Million)
Table 22 Western Europe Connective Tissue Disease Market by Diagnosis, 2017 – 2023, (USD Million)
Table 23 Western Europe Connective Tissue Disease Market by Treatment, 2017 – 2023, (USD Million)
Table 24 Western Europe Connective Tissue Disease Market by End Users, 2017 – 2023, (USD Million)
Table 25 Eastern Europe Connective Tissue Disease market by Diagnosis, 2017 – 2023, (USD Million)
Table 26 Eastern Europe Connective Tissue Disease Market by Treatment, 2017 – 2023, (USD Million)
LIST OF FIGURES

Figure 1 Research Process
Figure 2 Segmentation for Connective Tissue Disease Market
Figure 3 Segmentation Market Dynamics for Connective Tissue Disease Market
Figure 4 Global Connective Tissue Disease market Share, by Diagnosis 2016
Figure 5 Global Connective Tissue Disease market Share, by Treatment 2016
Figure 6 Global Connective Tissue Disease market Share, by End Users, 2016
Figure 7 Global Connective Tissue Disease market Share, by Region, 2016
Figure 8 North America Connective Tissue Disease market Share, by Country, 2016
Figure 9 Europe Connective Tissue Disease market Share, by Country, 2016
Figure 10 Asia Pacific Connective Tissue Disease market Share, by Country, 2016
Figure 11 Middle East & Africa Connective Tissue Disease market Share, by Country, 2016
Figure 12 Global Connective Tissue Disease market: Company Share Analysis, 2016 (%)
Figure 13 Abbott Laboratories: Key Financials
Figure 14 Abbott Laboratories Segmental Revenue
Figure 15 Abbott Laboratories Geographical Revenue
Figure 16 Bayer AG: Key Financials
Figure 17 Bayer AG Segmental Revenue
Figure 18 Bayer AG Geographical Revenue
Figure 19 F. Hoffmann-La Roche Ltd: Key Financials
Figure 20 F. Hoffmann-La Roche Ltd: Segmental Revenue
Figure 21 F. Hoffmann-La Roche Ltd: Geographical Revenue
Figure 22 Pfizer: Key Financials
Figure 23 Pfizer Segmental Revenue
Figure 24 Pfizer Geographical Revenue
Figure 25 AutoImmune Inc.: Key Financials
Figure 26 AutoImmune Inc.: Segmental Revenue
Figure 27 AutoImmune Inc. Geographical Revenue
Figure 28 Johnson & Johnson: Key Financials
Figure 29 Johnson & Johnson: Segmental Revenue
Figure 30 Johnson & Johnson: Geographical Revenue
Figure 31 Amgen Inc.: Key Financials
Figure 32 Amgen Inc.: Segmental Revenue
Figure 33 Amgen Inc.: Geographical Revenue